Policy Implications of Artificial Intelligence and Machine Learning in Diabetes Management

Area of Science:

• Diabetes care technology
• Artificial intelligence in medicine
• Health services research

Background:

• Machine learning (ML) is increasingly explored for diabetes screening, diagnosis, and management.
• Current ML applications in diabetes show varied success, with many models not translating to practical, real-world solutions.
• A significant gap exists between ML developers, regulatory bodies, healthcare providers, and patients.

Purpose of the Study:

• To review the current state of ML applications across different facets of diabetes care.
• To identify critical challenges hindering the effective implementation of ML in diabetes management.
• To explore strategies for maximizing the potential of ML in improving diabetes outcomes.

Main Methods:

• Literature review of current machine learning applications in diabetes.
• Analysis of challenges in translating ML models into clinical practice.
• Examination of regulatory approaches and stakeholder collaborations.

Main Results:

• ML has demonstrated notable success in automated insulin delivery systems and diabetic retinopathy screening.
• The application of ML in other areas of diabetes management remains in its nascent stages.
• The Food & Drug Administration (FDA) is actively developing frameworks for expedited and safe technology adoption.

Conclusions:

• Machine learning holds substantial potential for advancing diabetes care and management.
• Enhanced collaboration between regulatory bodies, researchers, clinicians, developers, and patients is crucial.
• Addressing implementation gaps is key to realizing the full benefits of ML for individuals and populations with diabetes.